Participant Recruitment, Enrollment and Characterization Core

与患者和医疗保健提供者的临床互动是研究研究成功的关键 建议在孢子和转化型卵巢癌研究中取得长期成功。这个 患者招募、登记和特征描述核心(在本文中称为临床核心) 提供临床专业知识和医生与患者的互动，这是成功治疗 完成孢子项目和试点活动的研究目标。 POCRC临床核心在招募大量女性队列方面表现出强劲的记录 患卵巢癌的风险(诊断前队列)和患有卵巢癌的妇女 诊断(发病病例队列)、治疗期间和随访(诊断后队列)。使用制服 接近、同意、登记和跟踪参与者的协议，已有3400多名女性登记参加 POCRC孢子(n=1740)孢子间(n=1112)和研究者发起的ROI资助(n=637)卵巢 癌症研究项目。 与前几年一样，太平洋卵巢癌研究联盟的持续成功取决于 招募参与者参加研究研究，包括临床试验。在我们以往成功的基础上， 经验，POCRC临床核心将完善参与者联系和登记程序，以支持所有 该孢子应用中的项目以及开发研究活动和合作 在孢子内外。与临床标本管理和 特征核心和生物统计和信息学核心，临床核心将确定参与者 临床试验，并提供满足研究所需的生物标本和相关临床数据 孢子的目标。临床核心中心的活动正在扩大，包括斯坦福大学的网站 加州帕洛阿尔托的大学医学中心和加州杜阿尔特的希望之城。再加上这些 SITES与我们联合西海岸主要卵巢癌研究中心的目标是一致的。 相关性(请参阅说明)： 这种卵巢孢子的目的是展示1)筛选高危女性的更好策略。 新的血清标志物和最先进的成像技术，无需另一项大型试验，通过整合我们的 第一阶段试验结果和正在进行的第111阶段疗效试验的报告；2)选择女性接受新辅助治疗 通过检测她们的血液是否具有可切除性特征来进行治疗；以及3)让女性对自己的血液进行免疫 以防止肿瘤复发。这些努力中的一项或多项取得成功将显著减轻 卵巢癌。

Clinical interaction with patients and health care providers is crucial to the success ofthe research studies proposed within the SPORE and to the long-term success of translational ovarian cancer research. The Patient Recruitment, Enrollment and Characterization Core (referred to in this document as the Clinical Core) provides the clinical expertise and the physician and patient interaction which is necessary for the successful completion of the research objectives of the SPORE projects and pilot activities. The POCRC Clinical Core has demonstrated a strong track-record in recruiting large cohorts of women at risk for developing ovarian cancer (pre-diagnosis cohort) and women with ovarian cancer at the time of diagnosis (incident cases cohort) and during treatment and follow-up (post diagnosis cohort). Using uniform protocols to approach, consent, enroll, and track participants, over 3400 women have been enrolled into POCRC SPORE (n=1740) inter-SPORE (n=1112) and investigator initiated ROI funded (n= 637) ovarian cancer research projects. As in prior years, continued success ofthe Pacific Ovarian Cancer Research Consortium depends on the recruitment of participants into research studies including clinical trials. Building on our prior success and experience, the POCRC Clinical Core will refine participant contact and enrollment procedures to support all ofthe projects in this SPORE application as well as developmental research activities and collaborations within and outside ofthe SPORE. Working in concert-with the Clinical Specimen Management and Characterization Core and the Biostatistics and Informatics Core, the clinical core will identify participants for clinical trials and provide bio-specimens and associated clinical data that are necessary to meet the research objectives ofthe SPORE. The activities of the Clinical Core are expanding to include sites at Stanford University Medical Center, Palo Alto, California and City of Hope, Duarte, California. The addition of these sites is consistent with our goal of uniting major ovarian cancer research centers along the West Coast. RELEVANCE (See instructions): The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase 1 trial results with reports from ongoing Phase 111 efficacy trials; 2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature; and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.